# Phosphate derivatives, process for preparation thereof and pharmaceutical compositions of the same.

## Abstract
New phosphate derivatives represented by the formula

## Claims
ClaimWhat is claimed is 1. A compound of the formula EMI22.1 wherein 1 R2and R3 are each hydroxy, alkoxy, alkanoylamino or protected hydroxy A is lower alkylene R4 is alkylammonio, cyclic ammonio or cyclic amino and R5 is oxido anion or hydroxy and pharmaceutically acceptable salt thereof. 2. A compound of claim 1, wherein Rl, R2 and R3 are each alkoxy. 3. A compound of claim 2, wherein R4 is alkylammonio. 4. The compound of claim 3, which is methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 choline phosphate , 5. The compound of claim 3, which is methyl 2 O methyl 3 O octadec yl Åa D xylofuranoside 5 choline phosphate . 6. The compound of claim 3, which is methyl 3 O methyl 2 O octadecyl a,ss D xylofuranoside 5 choline phosphate . 7. A compound of claim 2, wherein R4 is cyclic ammonio. 8. The compound of claim 7, which is methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 l pyridinio ethyl phosphate . 9. A compound of claim 2, wherein R4 is cyclic amino. 10. The compound of claim 9, which is methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 4 methyl 1 piperazinyl ethyl phosphate. 11. A compound of claim 1, wherein R1 and R3 are each alkoxy, R2 is hydroxy and R4 is alkylammonio, 12. The compound of claim 11, which is methyl 3 O octadecyl 8 D ribofuranoside 5 choline phosphate . 13. A compound of claim 1, wherein R1 and R2 are each alkoxy, R3 is hydroxy and R4 is alkylammonio. 14. The compound of claim 13, which is methyl 2 O octadecyl ss D xylofuranoside 5 choline phosphate . 15. A compound of claim 1, wherein R1 and R2 are each protected hydroxy, and R4 is alkylammonio. 3 16. A compound of claim 15, wherein R3 is alkoxy. 17. A compound of claim 15, wherein R3 is alkanoylamino. 18. A process for preparing a compound of the formula EMI24.1 wherein R1, R2 and R3 are each hydroxy, alkoxy, alkanoylamino or protected hydroxy A is lower alkylene R4 is alkylammonio, cyclic ammonio or cyclic amino and R5 is oxido anion or hydroxy or pharmaceutically acceptable salts thereof, which comprises by reacting a compound of the formula EMI24.2 wherein R1, R2, R3, A and R4 are each as defined above and X is an acid residue or its salt with an alkylamine or cyclic amine or a salt thereof. 19. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable, substantially nontoxic carrier or excipient.EMI25.1

## Description
PHOSPHATE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION OF THE SAME This invention relates to phosphate derivatives.More particularly, it relates to new phosphate derivatives which have antitumor activity, to process for preparation thereof, and to pharmaceutical composition comprising the same for therapeutical treatment of cancer in human being and animals. Accordingly, one object of this invention is to provide new and useful phosphate derivatives. Another object of this invention is to provide process for preparation of the phosphate derivatives A further object of this invention is to provide useful pharmaceutical composition comprising said phosphate derivatives as an antitumor agent. Still further object of the present invention is to provide a therapeutical method of treating cancer. The object phosphate derivatives of the present invention are novel and include the compounds of the formula I EMI2.1 wherein R1, R2 and R3 are each hydroxy, alkoxy, alkanoylamino or protected hydroxy A is lower alkylene R4 is alkylammonio, cyclic ammonio or cyclic amino and R5 is oxido anion or hydroxy and pharmaceutically acceptable salts thereof. In the above and subsequent description of the present specification, suitable examples and illustrations of the various definitions to be included within the scope of the invention are explained in details as follows. The term lower is intended to mean 1 to 6 carbon atom s and the term higher is intended to mean 7 to 25 carbon atoms, unless otherwise indicated. Suitable alkoxy for R1, R2 and R3 is straight or branched one containing 1 to 25 carbon atoms and may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy, eicosyloxy, heneicosyloxy, docosyloxy, tricosyloxy, tetracosyloxy, pentacosyloxy and the like. Suitable alkanoyl11 moiety in the alkanoylamino for Rl, R2 and R3 is straight or branched one containing 1 to 25 carbon atoms and may include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, eicosanoyl, heneicosanoyl, docosanoyl, tricasanoyl, tetracosanoyl, pentacosanoyl and the like. Suitable protective group of the protected hydroxy for R1, R2 and R3 is a conventional protective group for hydroxy such as ar lower alkyl e.g. benzyl, p methoxybenzyl, benzhydryl, trityl, trimethoxytrityl, etc. ,, lower alkanoyl as mentioned before, substituted lower alkanoyl e.g. trifluoroacetyl, chloroacetyl, etc. , lower alkoxycarbonyl e.g. methoxycarbonyl, trichloroethoxycarbonyl, tert butoxycarbonyl, etc. , aroyl e.g. benzoyl, toluoyl, xyloyl, naphtoyl, etc. , ar lower alkanoyl e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, etc. , aralkoxycarbonyl e.g.benzyloxycarbonyl, etc. , and two adjacent hydroxy groups may be protected as a cyclic acetal e.g. methyleneacetal, ethylideneacetal, benzylideneacetal, isopropylideneacetal, cyclohexylideneacetal, etc. , and the like. Suitable lower alkylene for A is straight or branched one containing 2 to 6 carbon atoms and may include ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene and the like. Suitable alkylammonio for R4 may include trialkylammonio such as trimethylammonio, triethylammonio, dimethylethylammonio, diethylmethylammonio, tripropylammonio, dimethylpropylammonio, tributylammonio, tripentylammonio, trihexylammonio, and the like. Suitable tcyclic ammonio for R4 may include a 5, 6 or 7 membered heterçocyclic ring containing at least one quarterly nitrogen atom such as oxazolio, isoxazolio, thiazolio, isothiazolio, 3H imidazolio, 2H imidazolio, 2H pyrazolio, 2H l,2,4 triazol l io, pyridinio, pyrazinio, pyrimidinio, pyridazinio, 1,2,4 triazin l io, 2H azepinio and the like, among which more preferable one is 6 membered heterocyclic ring, and the most preferable one is pyridinio. Suitable cyclic amino 1 for R4 may include a 5, 6 or 7 membered heterocyclic ring containing at least one tertiary nitrogen atom such as l pyrrolyl, l pyrrolinyl, 1 pyrrolidinyl, 1 imidazolyl, l pyrazolyl, piperidino, morpholino, l piperazinyl, 2 imidazolin 1 yl, 2 pyrazolidinyl l homopiperazinyl, homopiperidino, homomorpholino, and the like, among which preferable one is 6 membered heterocyclic ring, and the most preferable one is 1 piperazinyl. 4. The above cyclic ammonio or cyclic amino group forR4 may be substituted with lower alkyl e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, hexyl, etc. . It is to be noted that the compound having a cyclic amino group for R and hydroxy group for R5 may be nomenclated as an intramolecular salt such as a cyclic ammonio, for example, l pyrrolio, l piperidinio, 4 morpholinio, l piperzinio, l imidazolinio and the like. It is to be understood that there may be one or more stereoisomeric mixture such as optical isomer s due to asymmetric carbon atom s in the molecules, and these isomers are also included within the scope of the present invention. For instance, the compounds I include the ones where each substituent R1, Rz and R3 being bonded below or above the plane of the tetrahydrofuran ring of the compounds I, such as a andB isomer of xylofuranose, ribofuranose, arabinofuranose, lyxofuranose and the derivatives thereof. Suitable pharmaceutically acceptable salts of the object compounds I are conventional non toxic salts and may include an acid addition salt such as an inorganic acid addition salt e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc. , an organic acid addition salt e.g., oxalate, maleate, lactate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc. or a salt with an amino acid e.g., arginine aspartic acid, glutamic acid, etc. , a salt with a base such as alkali metal salt e.g., sodium salt, potassium salt, etc. , and the like. The object compounds I of the present invention can be prepared by the following process.EMI5.1 wherein R1, R2, R3, A, R4 and R5 are each as defined above, X is an acid residue, and 4 Ra is alkylamine or cyclic amine. That is, the object compounds I and salts thereof can be prepared by reacting a compound II or its salt with an amine compound III or its salt. Suitable acid residue for X may include halogen e.g. fluorine, chlorine, bromine, iodine , acyloxy e.g. benzenesulfonyloxy, tosyloxy, etc. , and the like. Suitable alkylamine or cyclic amine for R4a is the one corresponding to alkylammonio, cyclic ammonio or cyclic amine for R4 as illustrated before. Suitable salt of the compound tII is an alkali metal salt as exemplified before for the compound I . Suitable salt of the compound III is an acid addition salt as exemplified before for the compound IJ. This reaction is usually carried out in a solvent such as acetone, methanol, tetrahydrofuran, chloroform, benzene or any other solvent which does not adversely affect the reaction. In case that the compound III or its salt is liquid, it can also be used as a solvent. . The reaction temperature is not critical and the reaction is preferably carried out under warming or heating. The object compound I may occasionally be obtained as a salt with the acid residue X anion . The above salt can optionally be transformed to another salt or the corresponding intramolecular salt by a conventional method, such as treatment with an ion exchange resin, or treatment with silver ion. Some of the starting compounds II and their salts are novel and they can be prepared by the methods as shown in the Examples or the methods chemically equivalent thereto. The following pharmacological test data show that the object compounds I of the present invention exhibit high anti tumor activity. Test Method Groups of eight female BALB c mice, aged 8 9 weeks and weighing 18.0 22.5 g were used. Fibrosarcoma Meth A hereinafter referred to asMeth A was successively transferred every 7 days intoBALB c mice by intraperitoneal inoculation of the ascites cells thereof and the Meth A in the ascites cells as harvested 6 or rdays after the inoculation was used as tumor cells. Each of the 3AL3 c mice was inoculated intrapleurally with 5 x 105 Meth A cells in 0.1 ml Hanks solution. Test compound was dissolved in phosphate buffer saline solution, and was injected into pleural cavity to each of the mice in doses of 100 pug 0.05 ml mouse three times, i.e. before 14 days, after 1 hour and after 3 days of tumor implantation. The control group was given with a vehicle alone in the same way. The antitumor activity of the test compound was estimated by comparing mean survival time of the two groups. T Mean survival time of the medicated group C Mean survival time of the control groupTest Compound Ex 4 3 EMI7.1 Ex 6 7 EMI8.1 Control Compound rac l O Octadecyl 2 O methyl glycerol 3 phosphorylcholine which is described in British Patent No. 1583661.Test ResultsEMI8.2 tb SEP Anti tumor SEP activity tb SEP Compounds SEP a SEP C tb SEP Ex SEP 4 3 SEP 408 tb SEP Ex SEP 6 7 SEP I SEP 383 tb Control SEP Compound SEP 302.8 tb a T C x 100 As being apparent from the above test results, the object compound I1 of the present invention is useful as an antitumor agent. The effective ingredient may usually be administered with a dose of 0.1 mg kg to 500 mg kg, 1 to 4 times a day in a preparations such as tablet, granule, powder, capsule, syrup, injection, suppository and the like. However, the above dosage may be increased or decreased according to the age, weight or conditions of a patient or the administering method. The above mentioned pharmaceutical preparations can be prepared in a conventional manner by using conventional carriers and additives. The present invention is illustrated by the followingExamples in more detail.Example 1 1 A mixture of methyl 2 O methyl ss D xylofuranoside 3.45 g , trityl chloride 5.85 g , triethylamine 5 ml , and 4 dimethylaminopyridine 0.2 g in dry N,N dimethylformamide 15 ml was stirred for 10 hours at ambient temperature. The resulting mixture was poured into water 200 ml and extracted with diethyl ether. The combined extracts were washed with water, dried, and evaporated under reduced pressure. The oily residue was purified by column chromatography on silica gel 100 g, elution by benzene and then chloroform to give 4.90 g of methyl 2 O methyl 5 O trityl a,6 D xylofuranoside as an oil. IR film 3500, 3050, 2900, 2800, 1595, 1490, 1445 cm 1 ,. 2 To a solution of the above compound 4.80 g in dry N,N dimethylformamide 24 ml was added sodium hydride 0.82 g, 50 oil dispersion in one portion.After the mixture was stirred for one hour at ambient temperature, a solution of l bromooctadecane 4.18 g in dry N,N dimethylformamide 12 ml was added dropwise thereto. The resulting mixture was stirred for 24 hours at ambient temperature and then poured into ice water 200 ml . The separated oil was extracted with diethyl ether. The combined extracts were washed with water, dried, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel 160 g, elution by benzene and then benzene chloroform 4V 1V to yield 3.3 g of methyl 2 O methyl 3 O octadecyl 5 O trityl ss D xylofranoside as a colorless oil oil and 2.76 g of the a isomer as a colorless oil. isomer IR film 3050, 3000, 1595, 1490, 1460, 1450 cm a isomer IR film 2930, 2850, 1460, 1445 cm 3 To a solution of methyl 2 O methyl 3 O octadecyl 5 O trityl ss D xylofuranoside 3.2 g in dry methylene chloride 32 ml was added trifluoroacetic acid 3.2 ml in one portion at ambient temperature. After stirring for 1.5 hours at the same temperature, the yellow solution was washed with water, aqueous sodium bicarbonate and water succesively, dried, and evaporated under reduced pressure. The residue was triturated in n hexane to remove triphenylcarbinol by filtration.The filtrate was evaporated and then the residue was purified by column chromatography on silica gel 40 g, elution by chloroform to yield 1.21 g of methyl 2 O methyl 3 o octadecyl ss D xylofuranoside as a thick oil. IR film 3500, 2910, 2850, 1465 cm 4 To a mixture of the above compound 1.15 g and triethylamine 0.56 g in dry methylene chloride 5 ml was dropwise added a solution of 2 bromoethylphosphorodi chloridate l.33 g in dry methylene chloride 2 ml over a period of 10 minutes at 50C. After the addition was complete, the mixture was stirred for 8 hours at ambient temperature and then cooled in an ice bath. To the cold solution was added dropwise a mixture of pyridine 3 ml and water 1.5 ml over a period of 2 minutes.The ice bath was removed and the mixture was stirred for one hour at ambient temperature to hydrolyze phosphoroc hloridate derivative and then evaporated to dryness.The residue was dissolved in a mixture of ethyl acetare 25 ml and diethyl ether 25 ml . The solution was washed with 10 aqueous hydrochloric acid and brine, dried, and evaporated to yield 1.8 g of methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 bromoethyl phosphate as a waxy solid. IR Nujol 1460, 1375, 1260 cm NMR CDC13 ppm 0.86 m, 3H , 1.27 s, 32H , 3.42 s, 6H , 3.50 m, 4H , 3.72 m, 1H , 3.90 dd, 1H, J 8, 2.5Hz , 4.36 m, SH ,4.86 s, 1H 5 A mixture of the above compound 1.7 g and 30 aqueous trimethylamine 5.4 g in methanol 11 ml was stirred at 500C for 7.5 hours. An insoluble material was filtered off and the filtrate was evaporated under reduced pressure. The residue was dissolved in 90 aqueous methanol 17 ml and treated with silver acetate 1.13 g for 1.5 hours with vigorous stirring.The precipitates were removed by filtration and washed with methanol. The combined filtrate and washings were evaporated to dryness. The resulting solid was chromatographed on silica gel 35 g, elution by CHCl3 CH3OH H2O 65 25 2 to give 1.0 g of methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 choline phosphate which was purified by recrystallization from chloroform acetone. mp. 2000C dec. IR Nujol 3400, 1460, 1375, 1250 cm 1 NMR CDCl3 ppm 0.90 m, 3H , 1.28 s, 32H , 3.33 s, 6H , 3.35 m, 2H , 3.40 s, 9H , 3.68 m, 1H , 3.84 m, 3H , 4.10 m, 1H , 4.36 m, 4H , 4.82 s, 1H Anal. Calcd. for 930H62NO8P.2H2O, C 57.03, H 10.53, N 2.22 Found, C 56.15, H 10.60, N 2.18Example 2 Methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 l pyridinio ethyl phosphate 0.75 g was obtained by reacting methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 bromoethyl phosphate 2.0 g with pyridine 5 ml in a similar manner to that of Example 1 5 . mp. 1100C dec. IR Nujol 3360, 1640, 1495, 1250 cm NMR CD30D ppm 0.90 m, 3H , 1.30 m,32H , 3.37 s, 3H , 4.00 s, 3H , 3.1 4.1 m, 6H , 4.2 4.5 m, 3H , 4.78 5.00 m, 3H , 8.00 9.1 m, 5H Anal. Calcd. for C32H58NO8P H2O, C 60.64, H 9.54, N 2.21 Found, C 60.94, H 9.31, N 2.19Example 3 Methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 4 methyl 1 piperazinyl ethyl phosphate 1.69 g was obtained as an oil by reacting methyl 2 O methyl 3 O octadecyl ss D xylofuranoside 5 2 bromoethyl phosphate 3.75 g with l methylpiperazine 6.1 ml in a similar manner to that of Example 1 5 . IR film 3370, 2400, 1650, 1460, 1215 cml NMR CDCl3 ppm 0.9 m, 3H , 1.3 m, 32H , 2.60 s, 3H , 2.7 4.6 m, 20H , 3.42 s, 6H , 4.82 s, 1H Anal. Calcd. for C32H65N208P H2O C 58.69, H 10.31, N 4.28 Found, C 58.99, H 10.05, N 4.34 Example 4 1 Methyl 2 O methyl 3 O octadecyl alpha D xylofuranoside 1.70 g was obtained from methyl 2 O methyl 3 Ooctadecyl 5 O trityl a D xylofuranoside 3.89 g in a similar manner to that of Example 1 3 . mp. 65.5 to 66.5 C IR Nujol 3250, 3100, 1130 cm 2 Methyl 2 O methyl 3 O octadecyl a Dxylofuranoside 5 2 bromoethyl phosphate 2.07 g was obtained as a waxy solid from the above compound 1.50 g in a similar manner to that of Example 1 4 . IR Nujol 1120, 1070, 1010 cm 1 3 Methyl 2 O methyl 3 O octadecyl a Dxylofuranoside 5 choline phosphate 1.65 g was obtained by reacting the above compound 2.04 g with 30 aqueous trimethylamine 6.49g in a similar manner to that ofExample l 5 . mp. 2070C dec. IR Nujol 3550, 3400, 3320, 1240, 1060 cm 1 NMR CDC13 ppm 0.88 m, 3H , 1.28 m, 32H , 3.2 3.6 m, 15H , 3.6 4.5 m, llH , 4.92 d, 1H, J 4Hz Anal. Calcd. for C30H62NO8P 2H20 C 57.03, H 10.53, N 2.22 Found, C 57.60, H 10.32, N 2.22Example 5 1 l,2 O Isopropylidene 3 O octadecyl 5 O trityl a D xylofuranose 22.55 g was obtained as an oil from 1,2 O isopropylidene 5 O trityl a D xylofuranose 21.6 g in a similar manner to that of Example 1 2 . IR film 3050, 3025, 2920, 2850, 1595, 1490, 1445, 1370 cm 1 2 1,2 0 Isopropylidene 3 O octadecyl alpha D xylofuranose 12.7 g was obtained as a waxy solid from the above compound 22.5 g in a similar manner to that of Example l 3 . IR Nujol 3500, 1460, 1375, 1080, 1005 cm 3 1 ,2 O Isopropylidene 3 O octadecyl a D xylofuranose 5 2 bromoethyl phosphate 6.36 g was obtained as an oil from the above obtained compound 4.42 g in a similar manner to that of Example 1 4 . 1 IR film 2910, 2850, 1460 cm 4 1, 2 0 Isopropylidene 3 O octadecyl a D xylofuranose S choline phosphate 3.37 g was obtained from the above compound 6.25 g in a similar manner to that of Example l 5 . mp. 217 to 2180C IR Nujol 3300, 1470, 1380, 1240, 1090, 1060, 1015 cm 1 NMR CDCl3 ppm 0.87 m, 3H , 1.24 s, 3H , 1.28 s, 32H , 1.45 s, 3H , 3.37 s, 9H , 3.4 4.4 m, 10H , 4.48 d, 1H, J 4Hz , 5.89 d, 1H, J 4Hz Anal. Calcd. for C31H62NO8P2H2O, C 57.83, H 10.33, N 2.18 Found, C 57.21, H 10.45, N 2.13Example 6 1 1,2 5,6 Di O cyclohexylidene 3 O octadecyl a D allofuranose 30.3 g was obtained from 1,2 5 ,6 di O cyclohexylidene a D allofuranose 23.8 g in a similar manner to that of Example 1 2 . mp. 43 to 44 C l IR film 2910, 2850, 1470, 1450, 1365 cm 2 A solution of the above compound 10.0 g in a mixture of acetic acid 200 ml and water 60 ml was heated at 60 C for 4.5 hours. The solvents were evaporated below 40 C under reduced pressure. The residue was purified by column chromatography on silicagel 150g, elution by benzene and then benzene acetone 10 l . The eluates containing the object compound were combined and concentrated to give 7.53 g of 1,2 O cyclohexylidene 3 Ooctadecyl a D allofuranose as an oil. IR film 3400, 2910, 2850, 1460, 1445 cm 1 3 To a stirred solution of the above compound 7.45 g in tetrahydrofurane 300 ml was added a solution of periodic acid 7.84 g in water 45 ml in one portion at ambient temperature. The stirring was continued for 1.5 hours at the same temperature. The solvents were evaporated to dryness.The residue was extracted with diethyl ether. The extracts were washed successively with water,an aqueous sodium bicarbonate solution and brine, dried and evaporated to give 7.25 g of crude product. The product was purified by column chromatography on silica gel 70 g, elution by benzene, benzene chloroform l l, and then chloroform to yield 6.81 g of l,2 O cyclohexylidene 3 O octadecyl a D ribo pentodialdo 1,4 furanose as an oil. IR film 3450, 2920, 2850, 1735 cm 1 4 To a stirred solution of the above compound 5.5 g in a mixture of methanol 27 ml and tetrahydrofurane 27 ml was added sodium borohydride 0.6 g in one portion at ambient temperature. After the mixture was stirred for 10 minutes at the same temperature, the excess of sodium borohydride was decomposed by the addition of 10 aqueous hydrochloric acid. The solvents were evaporated under reduced pressure and the residue was extracted with chloroform. The extracts were combined and washed with water, an aqueous sodium bicarbonate solution, and brine successively, dried, and evaporated to dryness to yield 5.6 g of 1,2 0 cyclohexylidene 3 O octadecyl a D ribofuranose as a crystal. mp. 35 to 370C IR Nujol 3400, 3300, 1455, 1375 cm 1 5 1,2 O Cyclohexylidene 3 O octadecyl a Dribofuranose 5 2 bromoethyl phosphate 5.29 g was obtained as an oil from the above compound 5.5 g in a similar manner to that of Example 1 4 . IR film 3450, 1460, 1455 cm 6 To a solution of the above compound 4.5 g in a mixture of dry methanol 45 ml and dry tetrahydrofuran 45 ml was added conc. sulfuric acid 1.35 g in one portion. The mixture was refluxed for 3 hours and then allowed to cool to ambient temperature. Barium carbonate 4. 9.0 g was added thereto. The resultant suspension was stirred for one hour at ambient temperature and then filtered off. The filtrate was evaporated to give 5.0 g of crude product, which was purified by column chromatography on silica gel 100 g, elution by chloroform and then 1 10 methanol in chloroform to yield 3.85 g of methyl 3 O octadecyl ss D ribofuranoside 5 2 bromoethyl phosphate as a waxy solid. IR Nujol 3420, 1470, 1225 cm 1 7 Methyl 3 O octadecyl B D ribofuranoside 5 choline phosphate 3.0 g was obtained from the above compound 3.7 g in a similar manner to that of Example l 5 . mp. 140 C IR Nujol 3400, 3200, 1460, 1245 cm NMR CDCl3 ppm 0.86 m, 3H , 1.28 s, 32H , 3.2 4.5 m, 23H , 4.88 s, lH Anal. Calcd. for C29II60N08P H2 s C 58.06, H 10.42, N 2.33 Found, C 57.70, H 10.68, N 2.33Example 7 1 To a stirred mixture of 1,2 O isopropylidene 3 amino 3 deoxy a D ribofuranose 3.8 g and triethylamine 4 ml in dry benzene 38 ml was dropwise added, a solution of octadecanoyl chloride 6.08 g in dry benzene 10 ml over a period of one hour in an ice bath.After stirring for 3 hours at ambient temperature, the mixture was washed successively with water, an aqueous sodium hydroxide solution, and water, dried, and evaporated to give crude product 8.28 g , which was purified by column chromatography on silica gel 160 g, elution by chloroform and then 1 methanol in chloroform to yield 3.29 g of l,2 O isopropylidene 3 octadecanoylamino 3 deoxy a D ribofuranose as a crystal. mp. 74 to 76 C IR Nujol 3350, 1650, 1530, 1460, 1380, 1255, 1205 cm 1 2 l,2 O Isopropylidene 3 octadecanoylamino 3 deoxy a D ribofuranose 5 2 bromoethyl phosphate 3.21 g was obtained as a waxy solid from the above compound 3.2 g in a similar manner to that of Example 1 4 . IR Nujol 3300, 1645, 1540 1460, 1380, 1255 cm Ú 3 1,2 0 Isopropylidene 3 octadecanoylamino 3 deoxy a D ribofuranose 5 chbline phosphate 1.90 g was obtained from the above compound 2.6 g in a similar manner to that of Example 1 5 . mp. 211 to 2180C dec. IR Nujol 3300, 1645, 1560, 1460, 1375, 1245 cm Ú NMR CDCl3 ppm 0.86 m, 3H , 1.27 m, 33H , 1.51 s, 3H , 2.20 m, 2H , 3.36 s, 9H , 3.6 4.4 m, 8H , 4.60 m, 1H , 5.82 d, lH,J 4Hz , 6.44 m, 1H Anal. Calcd. for C31H61N2O8P. 3 2H2O, C 57.47, H 9.96, N 4.32 Found, C 57.82, H 10.21, N 4.34Example 8 l Methyl 3,5 di O benzyl 2 O octadecyl ss D xylofuranoside 6.1 g was obtained as an oil from methyl 3,5 di O benzyl B D xylofuranoside 6.0 g in a similar manner to that of Example 1 2 . IR film 3010, 2900, 2850, 1450, 1110, 1060 cm 2 A solution of the above obtained compound 6.0 g in a mixture of methanol 120 ml , tetrahydrofurane 60 ml , and acetic acid 36 ml containing palladium on charcoal 10 , 3.0 g was hydrogenated at 4 atm hydrogen pressure for 24 hours. The catalyst was removed by filtration followed by washing with chloroform. The combined filtrate and washings were evaporated under reduced pressure to yield 4.5 g of crude methyl 2 0 octadecyl a, xylofuranoside as a waxy solid, which was used in the following step without further purification. IR Nujol 3370, 1465, 1375, 1110, 1045 cm 3 Methyl 2 O octadecyl 5 O trityl S D xylofuranoside 3.95 g was obtained as an oil from the above compound 4.44 g in a similar manner to that ofExample 1 1 . IR film 3500, 3050, 3010, 2910, 2840, 1595, 1490, 1465, 1445 cm 1 4 A mixture of the above compound 3.9 g , acetic anhydride 2 ml and dry pyridine 4 ml was heated at 800C. for 2 hours. The resultant mixture was poured into water 20 ml and the separated oil was extracted with diethyl ether. The extract was washed with 5 aqueous hydrochloric acid , water, aqueous sodium bicarbonate, water, and brine successively.After drying, the solvent was evaporated to give 4.1 g of methyl 3 O acetyl 2 O octadecyl 5 O trityl ss D xylofuranoside as an oil. IR film 3050, 3010, 2900, 2830, 1740, 1235 cm 1 5 Methyl 3 O acetyl 2 O octadecyl ss D xylofuranoside 1.67 g was obtained as a waxy solid from the above obtained compound 4.0 g in a similar manner to that of Example 1 3 . IR Nujol 3430, 1740, 1710, 1460, 1375, 1110, 1065 cm 1 6 Methyl 3 O acetyl 2 O octadecyl ss D ç xylofuranoside 5 2 bromoethyl phosphate 2.22 g was obtained as an oil from the above compound 1.6 g in a similar manner to that of Example 1 4 . IR film 2900, 2850, 1740 cm 7 A mixture of the above compound 2.15 g and 30 aqueous trimethylamine 6.6 g in methanol 13 ml was stirred at 500C for 9 hours. An insoluble material was filtered off and the filtrate was evaporated under reduced pressure. The residue was dissolved in methanol 5Oinl . To the solution was added 28 methanolic sodium methoxide 2 ml and the mixture was stirred for 6 hours at ambient temperature. The mixture was evaporated and the residue was dissolved in a mixture of methanol 10 ml , chloroform 5 ml , and water 5 ml . The solution was adjusted to pH 2 with 10 hydrochloric acid and passed through a mixed ion exchange column, containing AmberliteIRC 50 H 40 ml and IR 45 OH 40 ml . The eluates were evaporated to dryness to give 2.1 g of crude product, which was further purified by column chromatography on silica gel 42 g telution by CHCl3 CH3OH H2O 65 25 4 and recrystallization from chloroform acetone to give 0.33 g of methyl 2 O octadecyl ss D xylofuranoside 5 choline phosphate . mp. 217 to 2200C IR Nujol 3200, 1460, 1200, 1045 cm 1 NMR CDCl3 ppm 0.87 m, 3H 1.25 s, 32H , 3.23 s, 9H , 3.35 s, 3H 3.2 4.6 m, llH , 4.73 s, 1H Anal. Calcd. for C29H60NO8P 5 2H2O C 55.57, H 10.45, N 2.23 Found, C 55.43, H 10.33, N 2.07Example 9 1 To a solution of 5 O benzyl 1,2 O isopropylidene 3 O methyl a D xylofuranose 7.0 g in methanol 21 ml was added conc. hydrochloric acid 0.2 ml . The mixture was refluxes for 2 hours and then allowed to cool to ambient temperature. To the resultant mixture was added barium carbonate 2.0 g . The suspension was stirred for 2 hours andfilteredoff. The filtrate was evaporated under reduced pressure.The oily residue was purified by column chromatography on silica gel 150 g, elution by CHCl3, 1 3 CHC13 in methanol to give 2.4 g of methyl 5 O benzyl 3 O methyl D xylofuranoside and 3.25 g of methyl 5 O benzyl 3 O methyl 8 D xylofuranoside. a isomer, oil NMR CCl4 ppm 2.44 d,.1H, J 7Hz , 3.36 s,3H , 3.44 s, 3H , 3.58 m, 3H , 3.98 Cm, 1H , 4.18 m, 1H , 4.45 s, 2H , 4.79 d, lH, J SHz , 7.21 Cm, 5H ss isomer, oil NMR CC14 ppm 2.4B brs, 1H , 3.26 s, 3H , 3.30 s, 3H , 3.52 m, 3H , 3.98 m, 1H , 3.94 m, 1H , 4.48 s, 2H , 4.63 s, 1H , 7.21 m, 5H 2 Methyl S O benzyl 3 O methyl 2 O octadecyl alpha ,ss D xylofuranoside 9.5 g was obtained as an oil from the mixture of above a and ss isomer 5.9 g in a similar manner to that of Example 1 2 . IR film 2900, 1820, 1460, 1360, 1110 cm 1 3 Methyl 3 O methyl 2 O octadecyl a, D xylofuranoside 3.92 g was obtained from the above compound 9.4 g in a similar manner to that ofExample 8 2 . IR film 3350, 1460, 1375, 1120, 1065 cm 4 Methyl 3 O methyl 2 O octadecyl alpha ,ss D xylofuranoside 5 2 bromoethyl phosphate 5.15 g was obtained as an oil from the above compound 3.80 g in a similar manner to that of Example 1 4 . IR film 2900, 2840, 1460 cm 1 5 Methyl 3 O methyl 2 O octadecyl alpha ,ss D xylofuranoside 5 choline phosphate 3.42 g was obtained from the above compound 5.0 g in a similar manner to that of Example 1 5 . mp. 2200C IR Nujol 3350, 1645, 1460, 1375 cm 1 NMR CDCl3 ppm 0.87 m, 3H , 1.28 s, 32H , 3.3 4.5 m, 26H , 4.80 4.92 m, 1H Anal. Calcd. for C30H62NO8P for C30H62NO8P2H2O, C 57.03, H 10.53, N 2.22 Found, C 57.00, H 10.60, N 2.16